SCHEMBL1238629

SCHEMBL1238629

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CON2CCOCC2)[C@@H](O)[C@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
ADORA3 P0DMS8 2/20 0.65
ADORA2A P29274 2/20 0.65
ADORA2B P29275 2/20 0.65
DPP4 P27487 1/20 0.65
MEN1 O00255 1/20 0.65
SLC28A1 O00337 1/20 0.65
MAP3K7 O43318 1/20 0.65
SLC28A2 O43868 1/20 0.65
GAPDH P04406 1/20 0.65
MAPK1 P28482 1/20 0.65
STAT6 P42226 1/20 0.65
PI4KA P42356 1/20 0.65
KMT2A Q03164 1/20 0.65
PI4K2B Q8TCG2 1/20 0.65
DOT1L Q8TEK3 1/20 0.65
SLC29A1 Q99808 1/20 0.65
PI4K2A Q9BTU6 1/20 0.65
SLC28A3 Q9HAS3 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448172 0.94 ADORA1 (0.70) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8820093 0.91 ADORA1 (0.66) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL1237877 0.89 ADORA3 (0.50) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL13268716 0.87 ADK (0.64) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL24146591 0.87 P2RY1 (0.63) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL24145122 0.85 ADORA1 (0.61) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL27875834 0.85 P2RY1 (0.75) ADORA1SMN1; SMN2P2RY1P2RY2SRC
SCHEMBL6901066 0.85 DPP4 (0.69) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL6899705 0.85 DPP4 (0.69) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL6901068 0.85 DPP4 (0.69) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120296087-A1 MORPHOLINO-BASED ANTISENSE AGENT INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2012-11-22 US claimed
WO-2011018798-A2 MORPHOLINO-BASED ANTISENSE AGENT INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2011-02-17 WO claimed
CN-120058705-A Synthesis method of pharmaceutical intermediate PMO-G (N2-iBu) 苏州诺维康生物科技有限公司 2025-05-30 CN disclosed
CN-106795186-B Process for preparing morpholino oligonucleotides 味之素株式会社 2021-03-02 CN disclosed
CN-105228999-B Process for preparing morpholino oligonucleotides 味之素株式会社 2021-03-02 CN disclosed
US-9914745-B2 Morpholino-based antisense agent INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2018-03-13 US disclosed
CN-106795186-A The preparation method of morpholino oligonucleotide 味之素株式会社 2017-05-31 CN disclosed
CN-105228999-A The preparation method of morpholino oligonucleotide AJINOMOTO KK 2016-01-06 CN disclosed
US-20120296087-A1 MORPHOLINO-BASED ANTISENSE AGENT INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2012-11-22 US disclosed
WO-2011018798-A2 MORPHOLINO-BASED ANTISENSE AGENT INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2011-02-17 WO disclosed
WO-1997033590-A1 A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS NOVO NORDISK A/S (DK) 1997-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120296087-A1 MORPHOLINO-BASED ANTISENSE AGENT MYOF, OSBP2, SLCO2B1 ADORA1 424/4885SMN1; SMN2 874/4885ADORA3 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.